Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation.

BACKGROUND Optimal time in therapeutic range (TTR) of vitamin K antagonists (VKAs) is crucial for cardiovascular events (CVEs) prevention in non-valvular atrial fibrillation (NVAF). The relationship between temporal changes of TTR and the incidence of CVEs has been poorly investigated. We investigated 1) temporal trends of TTR in a long-term follow-up of NVAF patients; 2) the incidence of CVEs according to changes of TTR. METHODS Prospective observational study including 1341 NVAF outpatients (mean age 73.5 years, 42.5% male) starting VKAs. Patients were divided into 4 groups: Group 0: Optimal TTR, consistently ≥70% (n = 241); Group 1: Temporally worsening TTR, from above to below 70% (n = 263); Group 2: Temporally improving TTR, from below to above 70% (n = 270); Group 3: Suboptimal TTR, consistently <70% (n = 567). RESULTS In a mean follow-up of 37.7 months (4214.2 patient-years), 108 CVEs occurred (2.6%/year). Survival analysis showed a graded increased risk of CVEs in relation to temporal changes in TTR, with the worst outcomes in Groups 1 and 3 (log-rank test p = 0.013). Multivariable Cox proportional hazards regression analysis showed that Group 1 vs. 0 (HR: 2.096; 95%CI 1.061-4.139, p = 0.033), Group 3 vs. 0 (HR: 2.292; 95%CI 1.205-4.361, p = 0.011), CHA2DS2VASc score (HR:1.316; 95%CI 1.153-1.501, p < 0.001) and PPIs (HR:0.453; 95%CI 0.285-0.721, p = 0.001) were independently associated with CVEs. CONCLUSION A decrease of TTR <70% over time is observed in almost 20% of NVAF patients. Patients with worsening TTR temporally (ie. from initially above 70% to below 70%) have similar risk of CVEs of patients with consistently suboptimal anticoagulation.

• Publication year

  2018

• Venue

  European journal of internal medicine

• Publication date

  2018-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejim.2018.04.007PMID 29655807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anticoagulation Stability Depends on CHADS2 Score and Hepatorenal Function in Warfarin-treated Patients, Including Those with Atrial Fibrillation

  2017cited by this paper
• Efficacy and Safety of Proton Pump Inhibitors in the Long-Term Aspirin Users: A Meta-Analysis of Randomized Controlled Trials

  2017cited by this paper
• Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.

  2017cited by this paper
• Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation

  2017cited by this paper
• Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients

  2017cited by this paper
• Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation.

  2016cited by this paper
• Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms

  2016cited by this paper
• 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

  2016cited by this paper
• Adherence to oral anticoagulant therapy in patients with atrial fibrillation

  2016cited by this paper
• University of Chronic kidney disease, time in therapeutic range and adverse clinical outcomes in anticoagulated patients with non-valvular atrial fibrillation: observations from the SPORTIF trials

  2016cited by this paper
• Ezetimibe enhances and stabilizes anticoagulant effect of warfarin

  2016cited by this paper
• Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease.

  2016cited by this paper
• Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry

  2016cited by this paper
• Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials

  2016cited by this paper
• Risk of Bleeding and Stroke with Oral Anticoagulation and Antiplatelet Therapy in Patients with Atrial Fibrillation in Taiwan: A Nationwide Cohort Study

  2015cited by this paper
• Safety and efficacy of well managed warfarin

  2015cited by this paper
• Quality of Anticoagulation With Vitamin K Antagonists

  2015cited by this paper
• Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC

  2015cited by this paper
• Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors.

  2015cited by this paper
• Calidad de la anticoagulación con antagonistas de la vitamina K en España: prevalencia de mal control y factores asociados

  2015cited by this paper
• Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.

  2015cited by this paper
• The potential drug–drug interaction between proton pump inhibitors and warfarin

  2015cited by this paper
• The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease.

  2015cited by this paper
• Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation

  2013cited by this paper
• Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score.

  2013cited by this paper
• Risk factors of vitamin K antagonist overcoagulation.

  2012cited by this paper
• Atrial Fibrillation and Acid Reflux Disease

  2012cited by this paper
• Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. - A multicenter study of its status and infuential factors-.

  2011cited by this paper
• Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)

  2010cited by this paper
• Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range

  2008cited by this paper
• Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation: A Systematic Review

  2008cited by this paper
• Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?

  2008cited by this paper
• A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy

  1993cited by this paper

• Effect of the quality of anticoagulation on the risk of stroke, thrombotic events, hemorrhagic events, and death in patients with nonvalvular atrial fibrillation on acenocoumarol in Real-World Data

  2024cites this paper
• Drug management of atrial fibrillation in light of guidelines and current evidence: an Italian Survey on behalf of Italian Association of Arrhythmology and Cardiac Pacing

  2023cites this paper
• Anticoagulation Management in Patients Receiving Warfarin at Private Cardiac Centers in Addis Ababa, Ethiopia

  2023cites this paper
• Bleeding and mortality risk in patients implanted with mechanical prosthetic heart valves with and without thrombocytopenia. Insights from the nationwide PLECTRUM registry

  2022cites this paper
• Anticoagulation control, outcomes, and associated factors in long-term-care patients receiving warfarin in Africa: a systematic review

  2022cites this paper
• Sex‐based difference in anticoagulated patients with mechanical prosthetic heart valves and long‐term mortality risk

  2021cites this paper
• Current trends in the use of anticoagulant pharmacotherapy in the United Kingdom are changes on the horizon?

  2021cites this paper
• Time to Stable Therapeutic Range on Initiation of Warfarin as an Indicator of Control.

  2021cites this paper
• Sex‐influence on the time in therapeutic range (TTR) during oral anticoagulation with coumarin derivatives: Systematic review and meta‐analysis

  2021cites this paper
• How effective is pharmacotherapy for stroke and what more is needed? A focus on atrial fibrillation

  2021influential citation
• Patient-related factors associated with oral anticoagulation control: a population-based cohort study.

  2021cites this paper
• Análisis de la calidad de la anticoagulación con antagonistas de la vitamina K en tres escenarios clínicos en México

  2021cites this paper
• Anticoagulation Control, Outcomes, and Associated Factors in Patients with Atrial Fibrillation Receiving Warfarin at Tertiary Care Hospital in Ethiopia

  2021cites this paper
• Determinants of low‐quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study

  2020cites this paper
• Cancer‐specific ischemic complications in elderly patients with atrial fibrillation: Data from the prospective ATHERO‐AF study

  2020cites this paper
• Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants.

  2020cites this paper
• The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years

  2020cites this paper
• Integrated care management of patients with atrial fibrillation-far from optimal.

  2020cites this paper
• Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort.

  2019cites this paper
• Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people.

  2019cites this paper
• Tailored Practical Management of Patients With Atrial Fibrillation: A Risk Factor-Based Approach

  2019influential citation